AGIOS PHARMACEUTICALS INC's ticker is AGIO and the CUSIP is 00847X104. A total of 147 filers reported holding AGIOS PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 1.39 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,549 | +17.0% | 103 | +33.8% | 0.00% | – |
| Q2 2023 | $2,179 | +23.3% | 77 | 0.0% | 0.00% | – |
| Q1 2023 | $1,767 | -80.9% | 77 | -76.5% | 0.00% | – |
| Q4 2022 | $9,264 | +15.8% | 327 | +14.3% | 0.00% | – |
| Q3 2022 | $8,000 | +166.7% | 286 | +130.6% | 0.00% | – |
| Q2 2022 | $3,000 | -78.6% | 124 | -73.5% | 0.00% | – |
| Q1 2022 | $14,000 | -30.0% | 468 | -20.0% | 0.00% | – |
| Q4 2021 | $20,000 | -48.7% | 585 | -30.9% | 0.00% | – |
| Q3 2021 | $39,000 | -53.6% | 846 | -44.5% | 0.00% | – |
| Q2 2021 | $84,000 | +20.0% | 1,525 | +13.6% | 0.00% | – |
| Q1 2021 | $70,000 | +18.6% | 1,343 | -4.1% | 0.00% | – |
| Q4 2020 | $59,000 | +40.5% | 1,401 | +18.4% | 0.00% | – |
| Q3 2020 | $42,000 | -38.2% | 1,183 | -6.6% | 0.00% | – |
| Q2 2020 | $68,000 | +655.6% | 1,267 | +427.9% | 0.00% | – |
| Q1 2020 | $9,000 | – | 240 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Eagle Health Investments LP | 431,413 | $12,558,000 | 3.09% |
| Casdin Capital, LLC | 2,090,000 | $60,840,000 | 2.73% |
| Rock Springs Capital Management LP | 2,665,275 | $77,586,000 | 1.95% |
| Bellevue Group AG | 4,129,292 | $120,204,000 | 1.40% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,177,374 | $34,273,000 | 1.05% |
| Altium Capital Management LP | 66,196 | $1,927,000 | 0.64% |
| ArrowMark Colorado Holdings LLC | 1,295,948 | $37,725,000 | 0.33% |
| FARALLON CAPITAL MANAGEMENT LLC | 1,333,012 | $38,804,000 | 0.19% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 21,500 | $707,000 | 0.16% |
| Virtus ETF Advisers LLC | 11,541 | $336,000 | 0.15% |